Compare VALU & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | AVXL |
|---|---|---|
| Founded | 1931 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.5M | 251.1M |
| IPO Year | 1995 | 2013 |
| Metric | VALU | AVXL |
|---|---|---|
| Price | $33.14 | $2.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 1.0K | ★ 879.2K |
| Earning Date | 03-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 8.91 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $36,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.34 | ★ N/A |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $32.73 | $2.61 |
| 52 Week High | $40.50 | $13.99 |
| Indicator | VALU | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 31.88 |
| Support Level | N/A | $2.61 |
| Resistance Level | $38.26 | $3.50 |
| Average True Range (ATR) | 0.47 | 0.17 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 17.57 | 5.30 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.